Crown Bioscience, Inc. has entered into a strategic partnership with Shin Nippon Biomedical Laboratories (SNBL), a Japan-based company that provides preclinical and clinical drug development services.
SNBL will promote Crown’s translational services to its clients in Japan, and will serve as the exclusive representative for Crown’s services, including its collection of Patient Derived Xenograft (PDX) models.The companies will also look to co-develop new models and services leveraging their respective expertise in oncology, diabetes and non-human primate model development.
The partnership expands Crown’s international presence following its recent expansion into Europe with the acquisition of PRECOS Ltd. in July 2013. SNBL also has facilities across Japan, the U.S., China, and Cambodia.
Jean-Pierre Wery, president of Crown said, “This strategic partnership offers Crown an excellent opportunity to develop a greater understanding of the Japanese market in order to further develop unique cutting-edge models. It is the first time that SNBL has agreed to represent an overseas company in such a deal. We are delighted to be partnering with the largest preclinical contract research organization in Japan as part of our international business strategy to develop our services in the Far East.”
Ryoichi Nagata, chief executive officer and president of SNBL comments, “SNBL is committed to providing our customers with fast and precise results across the entire drug development spectrum, from early discovery research to late-stage clinical trials. This unique partnership with Crown will enable us to strengthen our service offering, and also to collaborate on a variety of pre-clinical projects, utilizing unique clinically relevant models, with a shared goal of improving patient care and treatment outcomes. Our expertise in preclinical development provides a perfect complement to Crown’s existing global services.”